NCT06195254Completed
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
A Retrospective Clinical Study of Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Carcinoma.
Source: ClinicalTrials.gov · Last updated 8 Jan 2024
Brief summary (registry, in English)
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC. The patients, diagnosed with locally advanced pancreatic cancer (LAPC) or locally recurrent pancreatic cancer (LRPC). LRPC or LAPC, undergoing SABT and PD-1 blockers in our hospital from December 2020 to April 2023 were reviewed consecutively. All patients provided written informed consent before treatment. The study was conducted in accordance with the Declaration of Helsinki, and it was approved by the Institutional Ethics Committee of Peking University Third Hospital.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 19 (actual)
- First submitted
- 22 Dec 2023
- Start date
- 1 Dec 2020
- Primary completion date
- 21 May 2023
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06195254
What you commit to
- Study type: Observational
- Participants enrolled: 19
- From 1 Dec 2020 to the primary completion date, 21 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The upper abdomen was previously treated with radiotherapy;
- the patients previously underwent immunotherapy of PD-1 or PD-L1 monoclonal antibody;
Other illness
- a history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency or other immune-related conditions requiring long-term oral hormone therapy;
- patients with active infectious disease, trauma and severe wounds;
- patients with any mental disorder;
Other
- unconfirmed mass;
- patients with other somatic comorbidities of clinical concern;
- pregnancy and lactation.
Who the study is looking for
- LRPC confirmed by pathologic or imaging diagnosis and LAPC confirmed by pathology;
- disease size ≥1 cm;
- KPS≥70;
- adequate hematological reserves, hepatic function, renal function and heart function;
- expected survival \> 3 months.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Junjie Wang Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.